FDA approves new eczema drug Dupixent
The U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Source: Food and Drug Administration - Category: American Health Source Type: news
More News: American Health | Corticosteroid Therapy | Dermatitis | Dermatology | Eczema | Food and Drug Administration (FDA)